Talecris Biotherapeutics Holdings Corp. Watch

from 10-K 5 pages Talecris Biotherapeutics Holdings Corp. 2009 Long-Term Incentive Plan Performance Shares Award Agreement

from 8-K 8 pages Voting Agreement Contrato De Compromisos Relativos Al Voto

from 8-K 2 pages Lawrence D. Stern Chairman and CEO Talecris Biotherapeutics, Inc. 79 Tw Alexander Drive 4101 Research Commons Research Triangle Park, Nc 27709 June 3, 2010 Your Employment Agreement (“Agreement”) Dated as of September 05, 2006 and Amended and Restated as of September 5, 2008 and Again as of November 6, 2008, Between You and Talecris Biotherapeutics Holdings Corp. (The “Company”) Expires as of September 4, 2010. the Compensation Committee of the Board of Directors Has Authorized Me to Give You Notice of Renewal Pursuant to Section 2 of the Agreement to Extend the Agreement Through September 4, 2011,on the Same Terms as Contained in the Agreement, Except as Follows

from 8-K 2 pages Lawrence D. Stern Chairman and CEO Talecris Biotherapeutics, Inc. 79 Tw Alexander Drive 4101 Research Commons Research Triangle Park, Nc 27709 June 3, 2010 Your Employment Agreement (“Agreement”) Dated as of September 14, 2005 and Amended and Restated as of October 10, 2008 Between You and Talecris Biotherapeutics Holdings Corp. (The “Company”) Expires as of October 9, 2010. the Compensation Committee of the Board of Directors Has Authorized Me to Give You Notice of Renewal Pursuant to Section 2 of the Agreement to Extend the Agreement Through October 9, 2011,on the Same Terms as Contained in the Agreement, Except as Follows: Very Truly Yours, Agreed: /S/ Lawrence Stern Lawrence Stern /S/ John M. Hanson Chairman and Chief Executive Officer John M. Hanson June 6, 2010 Date CC: Kari Heerdt, Svp Human Resources File 2

from 8-K 5 pages 1. Severance Benefits. if at Any Time: (I) Talecris Terminates Your Employment Without Cause (As Defined Below), or (II) You Resign From Your Position With Good Reason (As Defined Below), You Will Be Entitled To, Subject to the Terms of This Letter Agreement, an Amount in Cash (The “Severance Payment”) Equal to Twelve Months Current Base Salary Plus One Year’s Bonus at Target. in Addition, for Two Years Following the Date of This Agreement, You Will Be Eligible for an Additional Cash Payment as Part of Your Severance Payment Equal to Six Months Base Salary if You Become Eligible for a Severance Payment Following a “Change in Control” as Defined in the Talecris Biotherapeutics, Inc. 2009 Long Term Incentive Plan. the Severance Payment, Including Any Additional Severance Payment, Shall Be Paid to You in a Lump Sum Within Sixty (60) Days of Separation From Service. 2. Definitions. the Following Words and Phrases Have the Following Meanings When Used in This Letter Agreement

from 8-K 2 pages Lawrence D. Stern Chairman and CEO Talecris Biotherapeutics, Inc. 79 Tw Alexander Drive 4101 Research Commons Research Triangle Park, Nc 27709 May 25, 2010 Your Position and Role

from 10-Q ~5 pages Material contract

from 8-K 27 pages Talecris Biotherapeutics Holdings Corp. 7.75% Senior Notes Due 2016 Registration Rights Agreement

from S-1/A 7 pages Talecris Biotherapeutics Holdings Corp. 2009 Long-Term Incentive Plan Restricted Share Unit Award Agreement

from S-1/A 8 pages Talecris Biotherapeutics Holdings Corp. 2009 Long-Term Incentive Plan Stock Option Award Agreement

from S-1/A 23 pages ***Text Omitted and Submitted Separately Pursuant to Confidential Treatment Request Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 Master Consulting and Advisory Services Agreement

from S-1/A 67 pages Prolastin Directsm Amended and Restated Services Agreement

from S-1/A ~5 pages Amendment to Supply Agreement by and Between Bayer Healthcare LLC and Talecris Biotherapeutics, Inc

from S-1/A 43 pages Supply Agreement by and Between Bayer Healthcare LLC Biological Products Division Berkeley, California and Talecris Biotherapeutics, Inc. Raleigh, North Carolina

from S-1/A 60 pages Fractionation Services and Commercial Products Agreement ***Text Omitted and Submitted Separately Pursuant to Confidential Treatment Request Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 Between and Amongst Héma-Québec and Talecris Biotherapeutics Ltd. and Talecris Biotherapeutics Inc

from S-1/A 60 pages Contract Fractionation Services and Commercial Products Agreement Between and Amongst ***Text Omitted and Submitted Separately Pursuant to Confidential Treatment Request Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 Canadian Blood Services and Talecris Biotherapeutics Inc. and Talecris Biotherapeutics Ltd

from S-1/A 2 pages Second Amendment to Management Agreement

from S-1/A 3 pages First Amendment to Stockholders Agreement

from S-1/A 28 pages Talecris Biotherapeutics Holdings Corp. 2009 Long-Term Incentive Plan Plan Document

from S-1/A 5 pages Amendment to Agreement for Domestic and Global Relocation Services